Dapagliflozin 10 mg + Metformin 500 mg PCD Pharma

Brand Name

LIDAPA M 10/500 Tablet

Composition

Dapagliflozin 10 mg & Metformin 500 mg (Extended Release)

Therapeutic Use

ANTIDIABETICS

Size

10 x 10

Verified Exporter

Verified Seller

Trusted Pharma

Description

LIDAPA M 10/500 Tablet contains Dapagliflozin 10 mg and Metformin 500 mg extended release (ER), a combination of two oral antidiabetic medicines used to help improve blood glucose control in eligible adults with type 2 diabetes mellitus. Dapagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class, while metformin is a biguanide that primarily reduces glucose production in the liver and improves the body’s response to insulin.

This combination may be prescribed when a healthcare professional considers both medicines appropriate for an individual’s diabetes management plan. Treatment is generally used alongside dietary measures, physical activity and regular blood glucose monitoring. suitability depends on kidney function, other medical conditions, concurrent medicines and the approved product information.

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Businesses searching for a Dapagliflozin 10 mg + Metformin 500 mg ER Tablets manufacturer India can enquire about current product availability, approved specifications, manufacturing-source details and applicable quality documentation.

For pharmaceutical procurement teams evaluating a Dapagliflozin 10 mg + Metformin 500 mg ER Tablets manufacturer and supplier India, important considerations include composition accuracy, product authorization, extended-release formulation details, packaging specifications, batch traceability and commercial supply terms.

2. Key Ingredient

Composition:

Dapagliflozin 10 mg + Metformin 500 mg

Dapagliflozin: An SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, helping the body eliminate more glucose through urine.

Metformin ER: A biguanide antidiabetic medicine that primarily decreases glucose production in the liver and improves insulin sensitivity. The extended-release formulation is designed to release metformin over a longer period according to its approved formulation characteristics.

For businesses researching a Dapagliflozin 10 mg + Metformin 500 mg ER pharmaceutical company India, procurement assessments should cover the active ingredients, declared strengths, extended-release formulation, authorized product source and applicable regulatory documentation.

Companies looking for a Dapagliflozin 10 mg + Metformin 500 mg ER medicine manufacturer India should verify manufacturing details, approved labelling, batch documentation and relevant quality standards before entering into a supply arrangement.

3. Key Benefits

Complementary glucose-lowering action: Combines two medicines that lower blood glucose through different mechanisms.

Kidney-mediated glucose elimination: Dapagliflozin helps increase glucose excretion through urine.

Reduced liver glucose production: Metformin helps reduce hepatic glucose production and improve insulin sensitivity.

Extended-release component: Metformin ER is formulated for extended release according to the approved product specifications.

Combination treatment option: May simplify a treatment regimen for patients for whom both ingredients are prescribed in one Tablet.

Support for an overall diabetes plan: Can be used alongside appropriate diet, physical activity, monitoring and regular medical review.

The combination is not appropriate for every patient. Clinical suitability depends on kidney function, hydration status, tolerance, other medicines and the prescribing clinician’s assessment. It should not be described as a guaranteed way to prevent complications or as a replacement for lifestyle management.

Pharmaceutical buyers searching for a Dapagliflozin 10 mg + Metformin 500 mg ER supplier India should verify product authenticity, current availability, approved composition, shelf life and batch documentation.

An enquiry for a Dapagliflozin 10 mg + Metformin 500 mg ER Tablet wholesaler and distributor India may include stock availability, distribution eligibility, minimum order quantities, delivery coverage and applicable commercial terms.

Businesses seeking a Dapagliflozin 10 mg + Metformin 500 mg ER bulk supplier India should request a current quotation and confirm packaging details, storage requirements, batch traceability and quality documentation before procurement.

A Dapagliflozin 10 mg + Metformin 500 mg ER pharmaceutical distributor India should verify product availability, applicable licensing requirements and authorized promotional information before starting commercial activities.

4. How Does It Work?

The two active ingredients act through different pathways to help regulate blood glucose.

Dapagliflozin inhibits the SGLT2 protein in the kidneys. This reduces glucose reabsorption from filtered blood and increases glucose excretion through urine.

Metformin primarily reduces glucose production in the liver and improves insulin sensitivity, helping the body use insulin more effectively.

Together, these actions can support improved blood glucose control in appropriately selected adults with type 2 diabetes. Dapagliflozin can increase urination and fluid loss, while metformin requires particular attention to kidney function and the risk of a rare but serious condition called lactic acidosis.

5. Directions for Use

Dosage: Take only as prescribed by a qualified doctor. The prescribed regimen must account for the patient’s current treatment, kidney function, tolerability and approved product information.

Administration: Follow the approved product label. Metformin extended-release Tablets are generally taken with food to improve gastrointestinal tolerability.

Swallowing: Extended-release Tablets should generally be swallowed whole. Do not crush, chew or split them unless the specific product instructions explicitly allow it.

Regular timing: Follow the prescribed schedule consistently. Do not change the dose or stop treatment without medical advice.

Kidney function: Kidney function must be assessed before and during treatment as clinically indicated. Metformin is contraindicated in severe renal impairment, and dapagliflozin eligibility depends on the intended indication and kidney function.

Hydration: Follow medical advice about fluid intake, especially during hot weather, vomiting, diarrhoea or other conditions that may cause dehydration.

Missed dose: Follow the approved patient information leaflet or ask a doctor or pharmacist for guidance. Do not double the next dose unless specifically instructed.

Acute illness or surgery: Contact the treating clinician for instructions during serious illness, prolonged fasting, surgery or reduced food and fluid intake. Temporary interruption may be necessary in certain circumstances.

This is an antidiabetic combination, not an antibiotic; therefore, an antibiotic-style “complete the full course” instruction does not apply. Continue treatment according to the prescriber’s instructions.

6. Possible Side Effects

Possible side effects associated with this combination include:

Nausea or vomiting

Diarrhoea or abdominal discomfort

Reduced appetite

Increased urination

Genital fungal or yeast infections

Urinary tract infections

Dehydration, dizziness or low blood pressure

Important serious risks include:

Lactic acidosis: A rare but serious complication associated with metformin. Warning signs may include unusual weakness, muscle pain, difficulty breathing, abdominal discomfort, unusual sleepiness or feeling very unwell. Seek emergency medical care if suspected.

Diabetic ketoacidosis: Can occur with dapagliflozin, sometimes without markedly elevated blood glucose. Symptoms may include nausea, vomiting, abdominal pain, unusual tiredness and difficulty breathing.

Severe dehydration: Persistent dizziness, fainting or inability to maintain fluid intake requires prompt assessment.

Serious urinary or genital infection: Fever, back or side pain, or severe genital pain, swelling or redness requires urgent medical attention.

Hypoglycaemia: Risk may increase when the combination is used with insulin or sulfonylureas.

Vitamin B12 deficiency: Long-term metformin use may lower vitamin B12 levels in some patients.

This list is not exhaustive. Seek professional medical advice about persistent symptoms and urgent care for suspected serious reactions.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Allergies: Do not use if there is a known serious hypersensitivity to either active ingredient or any component of the formulation.

Kidney function: Kidney function must be assessed before treatment and monitored as clinically indicated. Metformin must not be used in severe renal impairment.

Lactic acidosis risk: Inform the clinician about kidney or liver problems, severe infection, dehydration, heavy alcohol intake, heart or respiratory conditions that may cause tissue hypoxia, or other significant medical issues.

Ketoacidosis risk: Tell the clinician about previous ketoacidosis, prolonged fasting, acute illness, major surgery, heavy alcohol intake or very low-carbohydrate diets.

Dehydration and low blood pressure: Use caution in patients with fluid loss, low blood pressure or concurrent diuretic treatment.

Pregnancy and breastfeeding: Consult a doctor before use during pregnancy, when planning pregnancy or while breastfeeding. The clinician should assess the most suitable diabetes treatment.

Drug interactions: Inform the doctor about all prescription medicines and supplements. Certain medicines and iodinated contrast procedures may require additional assessment or temporary treatment interruption.

Monitoring: Follow advice on blood glucose, kidney function and vitamin B12 monitoring where appropriate.

Storage: Store in the original packaging according to the approved product label and keep it out of reach of children.

This information is educational and does not replace the approved prescribing information for the specific formulation or individualized medical advice.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products for healthcare professionals and pharmaceutical business partners. Pharmaceutical distributors, wholesalers and eligible businesses should confirm current product availability, supply eligibility and commercial arrangements directly with the company.

Businesses searching for a Dapagliflozin 10 mg + Metformin 500 mg ER PCD pharma franchise India opportunity can enquire about the current product portfolio, territory availability, partner eligibility and applicable commercial terms.

For a Dapagliflozin 10 mg + Metformin 500 mg ER Tablets PCD pharma franchise enquiry, prospective partners can request information about product availability, minimum order requirements, promotional resources and relevant documentation.

Companies considering a Dapagliflozin 10 mg + Metformin 500 mg ER Tablet PCD franchise should verify whether this formulation is included in any current programme before making investment or promotional commitments.

Businesses researching Dapagliflozin 10 mg + Metformin 500 mg ER third party manufacturing India should first confirm whether the proposed company offers these services. Relevant checks include manufacturing permissions, applicable GMP compliance, product authorization, batch requirements and quality documentation.

A Dapagliflozin 10 mg + Metformin 500 mg ER Tablet third party manufacturer India enquiry should cover the facility’s regulatory status, approved formulation specifications, extended-release technology, batch-release procedures, packaging requirements and contractual responsibilities.

Companies investigating Dapagliflozin 10 mg + Metformin 500 mg ER contract manufacturing India should discuss manufacturing authorization, technical specifications, quality agreements, regulatory responsibilities, production feasibility and commercial terms with the proposed manufacturing partner.

Visit CardianCare’s official website at https://CardianCare.com/ to enquire about current product availability and applicable pharmaceutical business arrangements. Distribution, franchise and manufacturing services must be confirmed directly with the company before being represented as available.

For more information about LIDAPA M 10/500 Tablet (Dapagliflozin 10 mg + Metformin 500 mg ER), click here

Frequently Asked Questions

This combination is prescribed to help improve blood glucose control in eligible adults with type 2 diabetes mellitus, alongside diet, physical activity and medical supervision.

The declared composition is Dapagliflozin 10 mg and Metformin 500 mg extended release. Dapagliflozin is an SGLT2 inhibitor, while metformin is a biguanide antidiabetic medicine.

Dapagliflozin helps the kidneys remove more glucose through urine. Metformin primarily reduces glucose production in the liver and improves insulin sensitivity. Together, they support blood glucose management through complementary mechanisms.

The combination provides two different glucose-lowering mechanisms in one Tablet and may be suitable for patients who require both medicines. Benefits depend on individual clinical circumstances and appropriate prescribing.

Take it as prescribed by a doctor and follow the approved product label. Metformin ER Tablets are generally taken with food and should usually be swallowed whole. Do not crush or chew them unless the product instructions allow it.

Possible effects include nausea, diarrhoea, abdominal discomfort, increased urination, genital fungal infections and dehydration. Lactic acidosis and diabetic ketoacidosis are serious risks requiring urgent medical assessment if suspected.

Patients with kidney impairment, significant liver disease, dehydration, heavy alcohol use, previous ketoacidosis or conditions that increase lactic acidosis risk should discuss suitability with their doctor. Pregnancy and breastfeeding also require medical assessment.

It may be used with selected medicines when prescribed by a healthcare professional. Hypoglycaemia risk may increase when combined with insulin or sulfonylureas, and additional monitoring may be required.

Buyers should verify both active ingredients and strengths, the extended-release formulation, authorized product source, applicable regulatory documentation, batch traceability, shelf life, packaging, storage conditions and commercial supply terms.

Eligible pharmaceutical businesses can contact CardianCare through its official website to enquire about current product availability and applicable distribution or franchise arrangements. Third-party manufacturing and contract manufacturing services require direct confirmation.

Reviews

There are no reviews yet.

Be the first to review “Dapagliflozin 10 mg + Metformin 500 mg PCD Pharma”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line